Insmed (NASDAQ:INSM) Coverage Initiated at Raymond James Financial

Analysts at Raymond James Financial started coverage on shares of Insmed (NASDAQ:INSM) in a research report issued to clients and investors on Friday, MarketBeat reports. The firm set an “outperform” rating and a $200.00 price target on the biopharmaceutical company’s stock. Raymond James Financial’s target price points to a potential upside of 29.19% from the company’s current price.

A number of other equities research analysts also recently weighed in on INSM. Royal Bank Of Canada lifted their price target on shares of Insmed from $197.00 to $200.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Roth Mkm upgraded shares of Insmed to a “strong-buy” rating in a research report on Friday, January 23rd. Stifel Nicolaus boosted their price objective on shares of Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Truist Financial set a $205.00 price objective on shares of Insmed in a research report on Monday, January 12th. Finally, UBS Group lowered their price objective on shares of Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research report on Tuesday, January 6th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $212.09.

Insmed Stock Down 3.0%

NASDAQ INSM opened at $154.81 on Friday. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76. Insmed has a 1-year low of $63.81 and a 1-year high of $212.75. The company has a 50 day moving average of $150.47 and a 200-day moving average of $167.20. The company has a market cap of $33.42 billion, a price-to-earnings ratio of -24.15 and a beta of 1.10.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. The firm’s quarterly revenue was up 152.6% on a year-over-year basis. On average, equities research analysts expect that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Activity at Insmed

In other Insmed news, insider Michael Alexander Smith sold 19,638 shares of the business’s stock in a transaction on Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the sale, the insider owned 51,871 shares of the company’s stock, valued at approximately $7,831,483.58. The trade was a 27.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $163.22, for a total transaction of $1,746,290.78. Following the sale, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $49,159,415.70. The trade was a 3.43% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 198,992 shares of company stock worth $31,660,112. Corporate insiders own 3.00% of the company’s stock.

Institutional Trading of Insmed

Several institutional investors have recently modified their holdings of INSM. CIBC Private Wealth Group LLC grew its stake in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the last quarter. CoreCap Advisors LLC bought a new stake in shares of Insmed in the fourth quarter worth $27,000. Stone House Investment Management LLC bought a new stake in shares of Insmed in the third quarter worth $29,000. SBI Securities Co. Ltd. grew its stake in shares of Insmed by 404.9% in the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 166 shares during the last quarter. Finally, GraniteShares Advisors LLC bought a new stake in shares of Insmed in the fourth quarter worth $30,000.

Insmed News Roundup

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Raymond James initiated coverage with an “Outperform” rating and a $200 price target, providing a near‑term upside anchor for the stock. The Fly
• Positive Sentiment: HC Wainwright updated its multi‑year model: it cut FY2030 EPS but materially raised FY2027–FY2029 estimates (FY2027 to $0.88, FY2028 to $3.38, FY2029 to $6.15), and maintains a $245 price objective — signaling improving medium‑term profitability assumptions from a major biotech analyst. MarketBeat: HC Wainwright updates
• Positive Sentiment: Large institutional holders (including Norges Bank and Vanguard) have built meaningful positions recently, which supports a structural bid under the stock and reduces free‑float supply pressure. MarketBeat: Institutional holdings
• Neutral Sentiment: Coverage pieces and valuation debates (e.g., “Is it too late to consider Insmed?”) are circulating; these frame the stock as recovery vs. valuation trade and may amplify headline trading but don’t change fundamentals on their own. Yahoo: Is it too late?
• Neutral Sentiment: CEO William Lewis sold 10,699 shares under a pre‑arranged Rule 10b5‑1 plan; the sale is material in dollar terms but was preplanned and follows a pattern of scheduled dispositions. SEC Form 4
• Negative Sentiment: Short interest rose sharply in March (roughly a 37% increase to ~13.8M shares, ~6.6% of the float, ~4.7 days to cover), raising downside pressure from bearish bets and amplifying volatility on negative headlines.
• Negative Sentiment: Insmed will discontinue development of brensocatib for hidradenitis suppurativa after the Phase 2b CEDAR trial missed primary/secondary endpoints (placebo outperformed), removing that potential revenue stream and driving the recent selloff and a trading halt on the study news. Reuters: Program discontinued
• Negative Sentiment: Market reaction to the trial miss included a trading halt and sharp intraday declines, signaling elevated near‑term downside risk and headline sensitivity. Investing.com: Market reaction

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.